Dossier structure and content for pandemic-influenza-vaccine marketing-authorisation application - Scientific guideline
Table of contents
This document provides the basis for a fast track authorisation procedure for pandemic influenza vaccines within the European Union. It assists with the documentation to be included in the core pandemic dossier and pandemic variation application for inactivated influenza vaccines.
The quality requirements of this guideline have been replaced by the guideline on influenza vaccines - quality module.
Keywords: Pandemic influenza vaccine for human use, core pandemic dossier, mock-up vaccine, quality requirements, non-clinical requirements, clinical requirements
-
List item
Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision) - Superseded (PDF/144.89 KB)
Adopted
First published: 18/12/2008
Last updated: 18/12/2008
Legal effective date: 01/01/2009
EMEA/CPMP/VEG/4717/2003- Rev.1 -
List item
Draft guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision) - Superseded (PDF/141.59 KB)
Draft: consultation closed
First published: 30/05/2008
Last updated: 30/05/2008
EMEA/CPMP/VEG/4717/03- Rev.1 -
List item
Concept paper on the revision of the guideline on dossier structure and content for pandemic influenza marketing authorisation application (CPMP/VEG/4717/03) - Superseded (PDF/34.56 KB)
First published: 15/05/2007
Last updated: 15/05/2007
EMEA/CHMP/166042/2007